Dr. Xu Research Brings Successful Outcomes...
Ingredients:
MEBO consists of several natural ingredients including Radix Scutellariae, Rhizoma Coptidis, Cortex Phellodendri Chinensis, Oleum Sesami, and Cera Flava. All these raw materials are traditional Chinese medicinal ingredients with a long history of human use and have been extensively described in the ancient Chinese Materia Medica and the current Chinese Parmacopeia. In modern pharma-cological studies, individual crude medicinal ingredient has been identified with medical properties of anti-inflammatory, anti-microbial, anticoagulative relaxing smooth muscle of blood vessel, counteracting toxicity, or promoting tissue regeneration.
Although each raw material of MEBO has its traditional use as described in the Pharmacopeia of the P.R China, MEBO is an extract from the botanical materials with sesame oil and mixed beeswax, therefore it is a mixture. So it is the mixture of several ingredients (MEBO) provides all the mode of actions. This is the unique characteristics of botanical, differentiated from chemical synthetic drug. Sesame oil is the only Chinese material medica as an oil admitted in the Pharmacopoeia of the People's Republic of China.
The core technology of MEBO lies in in situ regeneration of tissues and organs of the human body by providing regenerative nutrients and establishing favorable regenerative environment in the body. Under the regenerative conditions provided by MEBO, the injured, diseased, transformed or aged cells in the tissue and organ can be replaced in situ with normal, healthy cells, thereby restoring physiological structure and function to the body. Lost fingers/toes of adult patients can be regenerated with near complete restoration of structure and function, including bones, muscles, nerves, blood vessels, connective tissues, fingernails and skin.
This product contains regenerative nutrients that have the ability to activate Regenerative somatic cells to transform into stem cells...
B e f o
r e
A
f
t
e r
7 Months
Patent No.: US 7,074,438 B2 Date of Patent: Jul. 11, 2006
Patent No.: US 6,685,971 B2 Date of Patent: Feb. 3, 2004
-
The only regenerative and scientific product listed in United States Development Policy
-
The only regenerative product with 30 patent technologies; U.S. and International
-
The only regenerative product incorporated into the phase III clinical trial program approved by FDA
